Shares of CeriBell (NASDAQ:CBLL - Get Free Report) have been assigned an average recommendation of "Buy" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $32.60.
A number of equities analysts have recently commented on CBLL shares. Bank of America started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a "buy" rating and a $32.00 target price on the stock. William Blair started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an "outperform" rating on the stock. TD Cowen raised their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, December 9th. JPMorgan Chase & Co. started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 target price on the stock. Finally, Canaccord Genuity Group started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a "buy" rating and a $30.00 target price on the stock.
Get Our Latest Research Report on CBLL
CeriBell Stock Up 4.4 %
NASDAQ:CBLL traded up $0.89 during trading hours on Friday, reaching $21.04. 257,470 shares of the company were exchanged, compared to its average volume of 304,478. CeriBell has a 52-week low of $18.69 and a 52-week high of $32.75. The company's 50 day moving average is $26.29.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. Research analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.
CeriBell Company Profile
(
Get Free ReportWe are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
